Spotlight On Israel: Blossoming Targeted Cancer Therapy Startups
Executive Summary
Scrip sat down with the CEOs of three emerging oncology companies in Israel that are all focused on targeted cancer treatments, to find out about upcoming milestones and novel technologies that are budding in the country.
You may also be interested in...
Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade
Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.
Interview: Alnylam President On Patisiran Lift-Off Plans
Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.
What Does AI Excellence Look Like In Big Pharma?
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.
Need a specific report? 1000+ reports available
Buy Reports